Brief: Aridis Pharmaceuticals Provides AR 501 Phase 2 Trial Update
17/01/2023 21:31
Jan 17 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :
* NEW APPROACHES TO TREATING INFECTIONS IN CYSTIC FIBROSIS
PATIENTS - AR 501 PHASE 2 TRIAL UPDATE
Source text for Eikon: ID:nGNX4Yj8mg
Further company coverage: ARDS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aridis Pharmaceuticals
See all newsBrief: Aridis Pharmaceuticals Inc - On September 7 Nasdaq Announced That It Would Delist Common Stock Of Co
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
U.S. STOCKS ON THE MOVE-Teladoc Health, NVDIA, Chipotle
U.S. STOCKS ON THE MOVE-Pinterest, Sunrun, Tencent Music